Recent studies have shown that arsenic trioxide (As 2 O 3 ) can induce complete remission in patients with acute promyelocytic leukemia (APL). We tested the efficacy and safety of As 2 O 3 for the treatment of patients with APL who had relapsed from or become refractory to all-trans retinoic acid (ATRA) and conventional chemotherapy in a prospective study. 
Introduction
Acute promyelocytic leukemia (APL) is a distinctive type of acute myeloid leukemia and characterized by chromosome translocations t (15;17) that disrupt the gene encoding a retinoic acid receptor-alpha (RAR␣) located on chromosome 17 and the promyelocytic leukemia (PML) gene on chromosome 15 . The PML-RAR␣ fusion protein causes a maturational block at the promyelocyte stage of myeloid differentiation. 1, 2 Differentiation therapy with all-trans retinoic acid (ATRA) in combination with chemotherapy has a major advance in the treatment of APL. [3] [4] [5] [6] However, approximately 20 to 30% of patients eventually relapse. Salvage therapy for these patients entailed high doses of cytotoxic chemotherapy which is often toxic and rarely curative. 7, 8 ATRA alone fails to induce a second remission in a majority. Bone marrow transplantation (BMT), although potentially curative, is an option for only a fraction of young relapsed patients. 9 Arsenic is a natural substance that has been used medically for over 2400 years. A long traditional use in Chinese medicine provided the basis for the introduction in the 1970s of 'Ailing-1', a solution of crude arsenic trioxide (As 2 O 3 ) and herbal extracts, for the treatment of APL. 10 The Harbin group reported the first series of APL patients treated with As 2 O 3 with more than 5-year survival in half of the patients. 11, 12 The Shanghai group confirmed the remarkable clinical efficacy of As 2 O 3 in patients with newly diagnosed and relapsed APL, 13 and the recent report from Shanghai showed that 40 (85.1%) of 47 relapsed APL patients achieved CR by As 2 O 3 therapy. 14 After the Chinese reports, a pilot study of As 2 O 3 was initiated in 12 relapsed patients in the USA in 1997, and of these 11 (92%) achieved a CR. 15 A multicenter trial was conducted in the USA based on these results and the CR rate in relapsed or refractory APL patients was 34 (85%) of 40. 16 Consequently, As 2 O 3 (Trisenox) was approved for the treatment of relapsed or refractory APL by the US Food and Drug Administration in September 2000.
In Japan, we conducted a prospective study of As 2 O 3 in patients with APL, who have relapsed or are resistant to chemotherapy using ATRA, at the Leukemia Study Group of the Ministry of Health, Labor and Welfare from February 1999, and we report the results here.
Patients and methods

Patients
Eligibility criteria were a diagnosis of APL by bone marrow morphology according to the FAB classification, confirmed in blood or bone marrow cells of t(15;17) translocation by conventional cytogenetic analysis, positive reverse transcriptases polymerase chain reaction (RT-PCR) assay for PML-RAR␣ or fluorescence in situ hybridization (FISH) analysis. Patients had to have relapsed or be resistant to standard antileukemic therapy, defined as at least one course of induction therapy using ATRA and an anthracycline. Written informed consent was obtained before the start of treatment. The protocol was reviewed and approved by the institutional review board of Hamamatsu University Hospital.
Treatment plan
Arsenic trioxide solution (10 mg in 10 ml) was kindly supplied from PolaRx Biopharmaceuticals (New York, NY, USA) and later from Cell Therapeutics (Seattle, WA, USA). Therapy was given according to the same protocol used in the multicenter phase II study in the USA. The drug was administered at a dose of 0.15 mg/kg given daily for a cumulative maximum of 60 days, being diluted in 500 ml of 5% dextrose and administered intravenously over 2 h. Treatment was discontinued before day 60 if the patients had achieved bone marrow remission or if substantial toxicity was observed. Patients who had achieved complete remission received one additional course of therapy beginning not less than 3 weeks and no later than 6 weeks after the completion of the initial course of therapy. The retreatment dose schedule used the same induction dose (0.15 mg/kg/day) administered for a cumulative total of 25 days.
Response criteria
Complete remission (CR) was defined using conventional criteria, as follows: cellular bone marrow aspirate with р5% blasts; peripheral blood leukocyte count у3 × 10 9 /l, or absolute neutrophil count у1.5 × 10 9 /l, and platelet count у100 × 10 9 /l. 'Bone marrow remission' includes the complete disappearance of all leukemic myeloblasts and promyelocytes by morphology, and a decrease in the percentage of myeloblasts to less than 5% of total bone marrow.
Monitoring
All patients stayed in hospital while receiving the arsenic trioxide therapy. The following tests were performed at least twice a week during induction therapy: complete blood count, coagulation profile, serum biochemical screening profile, serum creatinine and urinalysis. Patients were continuously monitored with wireless electrocardiography while receiving As 2 O 3 , and standard 12-lead electrocardiography was performed at least once a week.
Results
Patients
Fourteen patients with relapsed APL were treated from March 1999 to March 2001. One patient was in first relapse, eight in second relapse, three in third relapse, one in fourth relapse and one in fifth relapse. All patients had received extensive prior therapy with ATRA and cytotoxic drugs (Table 1) . Two patients had relapsed after BMT. Five patients were treated with Am80, a new retinoid derivative. 17 Leukocyte counts before As 2 O 3 treatment ranged from 0.3 to 9.3 × 10 9 /l, with a median of 1.4 × 10 9 /l. Median percentage of myeloblasts and promyelocyte in bone marrow was 61% (range, 16 to 95).
Treatment efficacy
Eleven (78%) of 14 patients achieved CR after induction treatment with As 2 O 3 ( Table 2) . One patient (patient 12) died of cerebral hemorrhage on day 21. Patient 13 had twice suffered from acute myocardial infarction prior to the development of APL. He relapsed four times and had been heavily treated with chemotherapy before the As 2 O 3 therapy. The ejection fraction was low (0.45) before the As 2 O 3 therapy. On day 38, nonsustained ventricular tachycardia (27 successive beats) was noticed when QTc interval was prolonged from 443 to 485 ms. He failed to achieve CR, and the As 2 O 3 therapy was discontinued on day 92. Patient 14 had a multiple liver abscess due to aspergillus before the As 2 O 3 therapy and had nonsustained ventricular tachycardia during the treatment. The As 2 O 3 therapy was not effective and was stopped on day 67.
The median duration of therapy in 11 patients who achi- 
Hyperleukocytosis
Hyperleukocytosis (у10 × 10 9 /l) developed during the As 2 O 3 therapy in five (36%) patients with the peak white blood cell (WBC) counts ranging from 16.4 to 55.0 × 10 9 /l (median, 43.5 × 10 9 /l) ( Table 2 ). In three patients, cytotoxic drugs were added to prevent the APL differentiation syndrome similar to the retinoic acid syndrome. 16 In contrast, in another nine patients, WBC counts decreased during the As 2 O 3 therapy, and G-CSF was administered for a few days in five patients when WBC counts decreased to around 0.5 × 10 9 /l.
Adverse events
Adverse events of the As 2 O 3 therapy are summarized in Table 3 . The most frequent adverse events were electrocardiogram abnormalities (Tables 2 and 3 ). Long QTc intervals (Ͼ440 ms) had already been noted in five of 14 patients before As 2 O 3 therapy. Prolongation of QT intervals from the pre-treatment levels was observed in 13 of 14 patients during the induction therapy with As 2 O 3 , and in five of nine patients during the second course of therapy after CR. Ventricular premature contractions (VPCs) were seen during 11 of 23 courses of therapy. Four patients developed nonsustained monomorphic contractions and received antiarrhythmic agents. Eight patients developed isolated VPCs, and in one of them As 2 O 3 was reduced to 0.1 mg/kg/day, and in five others As 2 O 3 was temporarily withdrawn. Serum electrolyte levels were within normal limits in all patients during the study. Other common adverse reactions were gastrointestinal symptoms such as nausea and vomiting, and dermatologic symptoms such as itching or erythematous change. Peripheral neuropathy, water retention and abnormal liver function tests were also observed. In two patients, liver function tests presented moderate abnormalities (AST, ALT up to 200 IU/l). After the withdrawal of As 2 O 3 , they recovered. In one patient, APL differentiation syndrome developed. This patient was treated with methylprednisolone, daunorubicin and enocitabine, and the symptoms subsided.
Morphologic changes of APL cells during the As 2 O 3 therapy
During the As 2 O 3 therapy, myelocyte-like cells were seen in bone marrow smears, and sometimes myelocytes showed hypogranulation. These cells showed morphologic features seen in myelodysplastic syndromes including imbalanced nuclear/cytoplasmic maturation and abnormal granulation. However, polymorphonuclear granulocytes did not increase during the As 2 O 3 therapy. A few degenerative nuclear frag- ATRA, all-trans retinoic acid; IDA, idarubicin; Ara-C, cytosine arabinoside; As 2 O 3 , arsenic trioxide; DNR, daunorubicin; BHAC, enocitabine; MIT, mitoxantrone; Am80, a new retinoid derivative; PBSCT, peripheral blood stem cell transplantation; RBMT, related donor bone marrow transplantation; UBMT, unrelated donor bone marrow transplantation.
mented cells could be observed in the bone marrow smears. After the completion of induction therapy, bone marrow cells gradually normalized.
Discussion
In the present study, 11 (78%) of 14 patients with relapsed or refractory APL achieved CR by the same protocol as the multicenter study in the USA. Six (60%) of 10 patients who Leukemia achieved CR and were initially positive for PML-RAR␣ had a negative RT-PCR test. These results are almost same as other studies. 14, 16 We treated patients with 6-mercaptopurine and methotrexate as post-remission treatments to obtain durable CR since Niu et al 14 suggested that the duration of CR tended to be related to post-remission treatment.
Recently, the result of a multicenter study in the USA was reported. 16 It showed that 34 (85%) of 40 patients achieved CR and 86% patients assessed by RT-PCR for PML-RAR␣ converted from positive to negative tests, and that the 18-month ATRA, all-trans retinoic acid; Ara-C, cytosine arabinoside; MTX, methotrexate; 6MP, 6-mercaptopurine; IDA, idarubicine; UBMT, unrelated donor BMT; VPC, ventricular premature contraction; VT, nonsustained ventricular tachycardia; PSVT, paroxysmal supraventricular tachycardia; ND, not done; NA, not applicable; CR, complete remission; NR, no response. overall survival and relapse-free survival estimates were 66% and 56%, respectively. It also showed that adverse events were common but generally self-limiting and reversible, tending to decrease over time. The most common drug-related adverse events in the USA study were hyperleukocytosis, APL differentiation syndrome and prolonged QT interval. Hyperleukocytosis was observed in 20 (50%) patients. However, with continuing arsenic trioxide therapy alone, the leukocytosis resolved in the majority of patients within 4-5 weeks of therapy. 16 The APL differentiation syndrome, which is clinically identical to the previously named retinoic acid syndrome, was seen only during remission induction and not during consolidation or maintenance therapy. Camacho et al 18 reported that leukocytosis was observed in 15 of 26 patients (58%) during As 2 O 3 therapy and the APL differentiation syndrome was observed in eight of 26 patients (31%). Patients who developed leukocytosis were significantly more likely to develop the APL differentiation syndrome. In the present study, hyperleukocytosis was seen in five (36%) patients. However, the APL differentiation syndrome developed in only one patient.
We previously reported prolonged QT interval and ventricular tachycardia in patients treated with As 2 O 3 . 19 In the present study including the previously reported patients, prolonged QT intervals were observed in 13 of 14 patients. Nine patients developed ventricular arrythmias (nonsustained monomorphic ventricular tachycardia or isolated VPCs), and four required treatment with antiarrhythmic agents. In the USA multicenter study, 63% of patients showed prolongation of QT interval and one patient had an asymptomatic 7-beat run of torsade de pointes. 16 Prolongation of the QT was observed between 1 and 5 weeks after As 2 O 3 infusion, and then returned towards baseline by the end of 8 weeks. As 2 O 3 also caused complete atrioventricular block. 20 QT prolongation can lead to a torsade de pointes-type ventricular arrhythmia, which can be fatal. A few serious cardiac adverse events were also reported recently. Unnikrishnan et al 21 Fatal hepatic damage was also reported. The hepatotoxicity was reportedly much higher and more severe in newly diagnosed patients than in relapsed ones. Therefore, Niu et al 14 suggested that As 2 O 3 should not be used as a first-line therapy. Other adverse events included peripheral neuropathy, fatigue, musculoskeletal pain and mild hyperglycemia. These adverse effects were generally manageable and did not require interruption of therapy. Low-dose As 2 O 3 (0.8 mg/kg) may reduce some toxic events including cardiac toxicity as Shen et al 23 reported.
The mechanism of As 2 O 3 is not completely understood. High-dose As 2 O 3 (1-2 m) induced APL cell apoptosis through direct or indirect disruption of mitochondrial transmembrane potentials due to opening of permeability transmission pores and release of preapoptotic factors from mitochondria to cytoplasm where they activate caspase and degradate specific substrates. [24] [25] [26] In contrast, low-dose As 2 O 3 (0.1-0.5 m) induces differentiation of APL cells through direct or indirect activation of RAR␣-RXR pathways in which coactivator and histone acetylase are involved. 27, 28 Activated RAR␣-RXR binds to retinoic acid response elements and induces the expression of differentiation-related genes. Myelogram during the As 2 O 3 therapy showed myelocytes and metamyelocytes with dysgranulopoiesis without increase of polymorphonuclear granulocytes and degenerative cells. 13 These findings suggested that As 2 O 3 induced partial differentiation and apoptosis.
Preclinical evidence supports the potential of arsenic trioxide against a number of different malignancies. Studies in cultured cells show that it inhibits growth and promotes apoptosis in myeloid leukemia, multiple myeloma, lymphoma, lymphocytic leukemia, and solid tumor cell lines. 29 We previously demonstrated that As 2 O 3 (1 m) markedly inhibited proliferation and induced apoptosis in some cell lines: NOL-3 (lymphoma cell line), NOP-1 (myeloma cell line), and suggested that As 2 O 3 might be clinically useful in lymphoid neoplasms. 30 We conclude that As 2 O 3 is highly effective, inducing clinical and molecular remission in patients with relapsed APL. Consequently, patients can be offered additional strategies to increase their long-term, disease-free survival. Cardiac toxicities in patients with QTc prolongation should be carefully monitored.
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